T3 Pharma raises CHF25m financing bringing total funding to date to CHF40m

– SWITZERLAND, Basel –  T3 Pharmaceuticals AG, Swiss biotech advancing immuno-oncology with its bacteria-based protein delivery platform, today announced the closing of its third financing round, raising over 25M CHF in a round co-led by existing investors, including the Boehringer Ingelheim Venture Fund, Reference Capital, Wille Finance, as well as private investors also participating in the round.…